Table 5 Combined analysis of the COL1A1 and COL1A2 polymorphisms and the risk of developing ACL injury
COL1A1 and COL1A2 | Control (N = 192) | Injured Group (N = 146) | P – valuea | Adjusted OR (CI 95%)b | Non-contact ACL (N = 67) | P – valuea | Adjusted OR (CI 95%)c |
|---|---|---|---|---|---|---|---|
rs1107946 + (rs412777 / rs4252 / rs2621215)e | N (%) | N (%) | |||||
WT / 3 WT | 13 (7.0) | 16 (11.0) | 0.32 | 1d | 8 (11.9) | 0.34 | 1d |
WT / 1 VAR | 58 (31.2) | 37 (25.5) | 0.39 (0.15–1.02) | 16 (23.9) | 0.43 (0.13–1.42) | ||
WT / 2 VAR | 24 (12.9) | 26 (17.9) | 0.58 (0.21–1.65) | 16 (23.9) | 0.91 (0.26–3.17) | ||
WT / 3 VAR | 12 (6.4) | 13 (9.0) | 0.65 (0.20–2.15) | 5 (7.5) | 0.62 (0.13–2.94) | ||
VAR / 3 WT | 13 (7.0) | 8 (5.5) | 0.25 (0.07–0.96) | 4 (6.0) | 0.33 (0.06–1.74) | ||
VAR / 1 VAR | 38 (20.4) | 20 (13.8) | 0.41 (0.14–1.15) | 7 (10.4) | 0.35 (0.09–1.40) | ||
VAR / 2 VAR | 20 (10.8) | 21 (14.5) | 0.79 (0.26–2.35) | 8 (11.9) | 0.96 (0.24–3.90) | ||
VAR / 3 VAR | 8 (4.3) | 4 (2.8) | 0.45 (0.10–2.13) | 3 (4.5) | 1.46 (0.25–8.46) | ||